---
schema_version: "secwatch.filing_event.v1"
accession: "0001662774-25-000011"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-03-24T23:59:59+00:00"
generated_at: "2026-05-24T06:41:42.611254+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Quince Therapeutics FY2024 net loss $56.8M; Phase 3 NEAT trial exceeds 50% enrollment

## Summary
- Net loss of $56.8M ($1.31/share) for FY2024; cash $40.8M provides runway into 2026.
- Phase 3 NEAT trial enrolled 61 participants (>50%); topline results expected Q4 2025.
- Received FDA Fast Track designation (June 2024); Phase 3 ATTeST results published in The Lancet Neurology.
- R&D $18.6M, G&A $17.6M; operating cash burn $31.9M includes $5M milestone and $17.1M goodwill impairment.
- Appointed Dr. William Whitehouse to SAB; USPTO allowed patent claims extending to 2036 for eDSP in A-T.

## SEC filing metadata
- accession: 0001662774-25-000011
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-03-24T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/0001662774-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000166277425000011/qncx-20250324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001662774-25-000011
- JSON: https://secwatch.observer/filing/0001662774-25-000011.json
- Plain text: https://secwatch.observer/filing/0001662774-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.